NGL FINECHEM
|
The Current P/E Ratio of NGL FINECHEM is 39.59.
| Share Price | ₹1,321.0 | Dec 10,2025 |
| Market Cap | ₹819.0 Cr | |
| Earnings-TTM | ₹20.7 Cr | TTM-Consolidated Results |
| Price/Earnings | 39.59x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of NGL FINECHEM
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹819.0 Cr] as on Dec 10,2025
(/) Earnings [ ₹20.7 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 39.59x ]
Thus, for NGL FINECHEM , the investors are currently willing to pay 39.59 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of NGL FINECHEM !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of NGL FINECHEM over the last five years.
Historical PE (Price/Earnings) ratio chart of NGL FINECHEM
PE Ratio Performance Analysis for NGL FINECHEM
- NGL FINECHEM 's p/e ratio for fiscal years ending Mar2025 to Mar2021 averaged 28.31x.
- NGL FINECHEM 's operated at median p/e ratio of 31.37x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, NGL FINECHEM 's p/e ratio peaked in Mar2023 at 36.22x.
- NGL FINECHEM 's p/e ratio hit its five-year low in Mar2021 of 16.74x.
How does NGL FINECHEM 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| NGL FINECHEM | 20.69 | 39.59 | 819.0 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 10,517.90 | 40.75 | 428,581.0 |
| DIVIS LABORATORIES LTD | 2,485.00 | 67.22 | 167,051.0 |
| CIPLA LTD | 5,453.86 | 22.06 | 120,289.0 |
| TORRENT PHARMACEUTICALS LTD | 2,140.00 | 59.98 | 128,367.0 |
| DR REDDYS LABORATORIES LTD | 5,721.40 | 18.25 | 104,421.0 |
| MANKIND PHARMA LTD | 1,767.06 | 50.17 | 88,649.9 |
| ZYDUS LIFESCIENCES LTD | 4,973.40 | 18.69 | 92,945.8 |
| LUPIN LTD | 4,347.53 | 21.59 | 93,866.9 |
| AUROBINDO PHARMA LTD | 3,447.75 | 19.73 | 68,035.1 |
| ABBOTT INDIA LTD | 1,508.95 | 39.47 | 59,563.0 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs NGL FINECHEM 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 18.25x |
| Max industry PE | 67.22x |
| Median industry PE | 39.47x |
| Average industry PE | 36.14x |
You may also like the below Video Courses